AstraZeneca admits in court for the first time that its coronavirus vaccine can cause thrombosis

For the first time, the Swedish-British pharmaceutical company AstraZeneca has admitted in court that its COVID-19 vaccine can cause thrombosis and thrombocytopenia syndrome (TTS). This is a rare consequence, the cause and effect of which has not yet been established.

According to the Daily Mail, a class action lawsuit was filed against the company for several million pounds. Dozens of families claim that they or their loved ones were injured or killed by the pharmaceutical giant's "defective" vaccine. Lawyers representing the plaintiffs believe that in some cases, compensation could reach 20 million pounds (just over $25 million).

AstraZeneca, which denies the claims, admitted in a legal document filed in London's High Court in February that its vaccine "may in very rare cases cause TTS."

TTS is a disease in which a person develops blood clots and a low platelet count (the latter usually helps the blood clot).

Although thrombosis has been considered a potential side effect of coronavirus vaccination for two years, this is the first time AstraZeneca has acknowledged the risk of TTS associated with the drug in court.

"We sympathize with all those who have lost loved ones or reported health problems. Patient safety is our highest priority... Based on a combination of clinical trials and real-world data, AstraZeneca-Oxford has consistently been shown to have an acceptable safety profile. Regulators around the world have consistently stated that the benefits of vaccination outweigh the risks of extremely rare potential side effects," the company said in a statement.

Representatives of the pharmaceutical giant also added that "the causal relationship in each case will be the subject of examination."

Only verified information is available on the OBOZ.UA Telegram channel and Viber. Don't fall for fakes!